COVID-19 Vaccination Strategies Should Consider Infection Risk in CAR T-cell Therapy Recipients - Episode 1

Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination

Muhammad Bilal Abid, MD, MRCP, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Now Viewing
EP. 1: Dr. Abid on the Potential Impact of CAR T-Cell Therapy on COVID-19 Vaccination
EP. 2: Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients
EP. 3: COVID-19 Vaccination Strategies Should Consider Infection Risks for CAR T-Cell Therapy Recipients
EP. 4: Efforts Needed to Evaluate How CAR T-Cell Therapy Recipients Respond to COVID-19 Vaccination

Muhammad Bilal Abid, MD, MRCP, assistant professor of medicine, Divisions of Hematology/Oncology and Infectious Diseases, Medical College of Wisconsin, discusses the potential impact of CAR T-cell therapy on the efficacy of COVID-19 vaccinations.

Patients who undergo CAR T-cell therapy should be revaccinated for COVID-19 following infusion, because the treatment may cause them to lose their response to the vaccine, according to Abid.

Additionally, it has been shown that if the patient received the COVID-19 vaccine within 6 months of receiving CAR T-cell infusion, response rates were not as favorable, Abid explains. Patients who received the vaccination more than 6 months after infusion have improved response rates, likely because they have better immune reconstitution, Abid concludes.